Detalles de la búsqueda
1.
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(3): 485-493, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37852306
2.
Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
J Am Acad Dermatol
; 90(6): 1232-1239, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38266683
3.
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
J Eur Acad Dermatol Venereol
; 37(2): 348-355, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300769
4.
Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
N Engl J Med
; 381(20): 1918-1928, 2019 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31722152
5.
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Rheumatology (Oxford)
; 61(3): 1035-1043, 2022 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34100922
6.
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 86(1): 77-85, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34343599
7.
Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Mod Rheumatol
; 32(2): 413-421, 2022 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34894266
8.
Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
Clin Exp Rheumatol
; 39 Suppl 132(5): 80-87, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34622764
9.
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Regul Toxicol Pharmacol
; 125: 104985, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34237378
10.
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
J Am Acad Dermatol
; 83(1): 96-103, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32032692
11.
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
J Am Acad Dermatol
; 82(2): 389-397, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31408686
12.
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
Rheumatology (Oxford)
; 57(7): 1253-1263, 2018 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29635379
13.
Rates of Cancers and Opportunistic Infections in Patients With Psoriatic Arthritis Compared With Patients Without Psoriatic Arthritis.
J Clin Rheumatol
; 22(5): 241-7, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26886439
14.
Incidence rates of suicidal behaviors and treated depression in patients with and without psoriatic arthritis using the Clinical Practice Research Datalink.
Mod Rheumatol
; 26(5): 774-9, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26882216
15.
Rates of Cardiovascular Disease and Major Adverse Cardiovascular Events in Patients With Psoriatic Arthritis Compared to Patients Without Psoriatic Arthritis.
J Clin Rheumatol
; 21(8): 405-10, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26406567
16.
Functional characterization of two clusters of Brachypodium distachyon UDP-glycosyltransferases encoding putative deoxynivalenol detoxification genes.
Mol Plant Microbe Interact
; 26(7): 781-92, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23550529
17.
Educational inequalities and cardiovascular risk factors. A cross-sectional population-based study in southern Spain.
Public Health Nurs
; 30(3): 202-12, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23586764
18.
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.
Am J Clin Dermatol
; 24(5): 809-820, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37316690
19.
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Am J Clin Dermatol
; 24(5): 837-847, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37233897
20.
Transgenic Arabidopsis thaliana expressing a barley UDP-glucosyltransferase exhibit resistance to the mycotoxin deoxynivalenol.
J Exp Bot
; 63(13): 4731-40, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22922639